摘要:
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy1-azobenzene derivative.
摘要:
A process for the preparation of a compound of formula (I): wherein Ar represents an optionally substituted aromatic carbocycle or heterocycle, and R?1 and R2¿ independently represent hydrogen, C¿1-10?alkyl, C(O)C1-10alkyl or optionally substituted aryl provided that R?1 and R2¿ are not both hydrogen which process comprises reacting together a compound of formula (II): Ar-X, wherein Ar is as defined in relation to formula (I) and X represents a leaving group with a compound of formula (III): wherein R?1 and R2¿ are as defined in relation to formula (I) under aqueous conditions in the presence of a Pd (II) salt, a ligand and a Group I or Group II metal hydroxide base at a pH greater than 7. Compounds of formula (I) may be hydrolysed to the corresponding hydrazine.
摘要:
The present invention features compounds useful for inhibiting Rnase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula (I) Y-(NR')k-U1-(NR'')l-A-(NR1)m-U2-(NR2)n-Z with substituents as described herein.
摘要:
A medical composition containing, as an active constituent, a nitroetheneamine derivative represented by formula (I) wherein R1 is a hydrogen atom, an optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or a cyano group; R?2 and R3¿ may be each a hydrogen atom, an optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or -A-R7 (wherein A is S, SO, SO¿2?, SO3, CO or CO2, and R?7¿ is a hydrogen atom, an optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group), or may form N=CR8R9 (wherein R?8 and R9¿ are each a hydrogen atom, an optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, an alkoxy or aryloxy group, a cyano group, a nitro group, or -A-R?7); R4 and R5¿ may be each a hydrogen atom, an optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, an alkoxy group, an amino group, an aryloxy group, -A-R7 , a cyano group, an ester group or a hydroxyl group, or may form N=CR8R9; R6 is a hydrogen atom, a nitro group, a cyano group, -A-R7, an optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, an alkoxy group, an amino group, or a halogen atom; and further R?1, R2, R3, R4 and R5¿ may form a ring containing or not containing a heteroatom, or a salt thereof as an active constituent.